Nicodrops Announces the Lawsuit with GlaxoSmithKline Has Been Dismissed

LA MESA, Calif., May 25, 2005 -- Nicodrops International Inc., a subsidiary of Nicodrops, Inc. (Other OTC: NCDP), developer of the drug-free, herbal dietary supplement smoking alternative lozenge(a), today announced an unfair competition lawsuit filed against it in February 2005 by GlaxoSmithKline Consumer Healthcare (NYSE:GSK) in Federal district court in the Western District of Pennsylvania has been settled to the mutual satisfaction of the parties and has been dismissed.

“Now that the suit is behind us, we can focus all our attention on expanding the Nicodrops franchise. We are absolutely committed to building shareholder value as we move forward,” said Christopher Calpito, president and CEO of Nicodrops, Inc.

About Nicodrops

Nicodrops Inc., La Mesa, CA, developed a drug-free, non-nicotine product which helps reduce the stress associated with not smoking, using all natural herbs(a). For more information go to http://www.nicodrops.com or call 1-866-844-5383.

This press release contains ``forward-looking statements’’ within the meaning of the Private Securities Litigation Act of 1995. The words ``believe,’’ ``expect,’’ ``anticipate’’, and ``project’’, and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Such statements may include, but not be limited to, projections of revenues, income or loss, expenses, plans, and assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future results could differ materially from those described in forward-looking statements.

(a) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any diseases.

Contact Information

David Donlin

Media Contact

Cervelle Group

Contact via E-mail